Moderna CEO warns China is pouring state money into mRNA technology

Key Points:

• Moderna's CEO Stéphane Bancel warns that while the U.S. is reducing mRNA funding, China is aggressively investing state money to challenge American leadership in biotechnology, particularly in mRNA technology.
• Bancel emphasizes the importance of maintaining drug manufacturing in the U.S., highlighting Moderna’s expanded facilities in Massachusetts to ensure advanced personalized medicines are produced domestically.
• The Chinese government has prioritized biotechnology as a strategic industry with significant state financing, while the U.S. Department of Health and Human Services is scaling back nearly $500 million in mRNA vaccine development projects.
• Moderna’s stock surged 177% after positive Phase 3 trial results for a personalized mRNA cancer treatment combined with Merck’s Keytruda, signaling mRNA’s potential beyond vaccines to oncology and rare genetic diseases.
• Bancel envisions Moderna evolving into a diversified biotech company focused on infectious diseases, cancer, and rare genetic disorders by the end of the year, leveraging innovative, cost-effective manufacturing processes.